In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

The company's innovative new product lineup and expansive list of patent-protected ... cash flows beyond developed markets. GSK's decision to divest its consumer business will likely unlock ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GlaxoSmithKline (GSK ... first announced the “strategic review” of Horlicks and other consumer healthcare nutrition products in March this year. Proceeds from a potential sale could be ...

The Nigerian economy has seen the closure of many companies, especially multinational firms, which threw many Nigerians into ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK cuts 2024 vaccine sales forecast for second time this year Strong specialty medicines offset lower vaccine sales - CEO Q3 EPS beats market expectations Shares down 3.9% at 0958 GMT Oct 30 ...

GlaxoSmithKline ... the product of the 1929 merger of British soapmaker Lever Brothers and the Dutch company Margarine Unie. The transnational company is one of the world’s largest consumer ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...